Physicians' Academy for Cardiovascular Education

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

3' education - Nov. 12, 2018 - Jane Wilcox, MD

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

3' education - May 31, 2017 - ESC HF 2017, Paris

Disappointing results with therapy for acute heart failure

3' education - Apr. 30, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

HFpEF in older adults: TTR amyloid, under diagnosed and treatable?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

3' education - Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

Iron deficiency in the new HF guidelines

3' education - Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

3' education - Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure news at the ESC

10' education - Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
##SCROLLER_ITEMS_FULL_TITLE##

Heart Failure news from ESC 2016 at a glance

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

10' education - June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

Initiation of ARNI in patients with acute decompensated heart failure

AHA 2018 - Chicago, IL, USA

3' education - Nov. 13, 2018 - Eric Velazquez, MD
Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.

AHA 2018 Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

AHA 2018 – Chicago, IL, USA

3' education - Nov. 12, 2018 - Jane Wilcox, MD
The pilot TRED-HF study evaluated a phased withdrawal of HF therapy in patients who responded well to therapy and found that this likely reflects remission rather than full recovery.

AHA 2018 The pilot TRED-HF study evaluated a phased withdrawal of HF therapy in patients who responded well to therapy and found that this likely reflects remission rather than full recovery.

Recovery after dilated cardiomyopathy often means remission rather than cure

AHA 2018 – Chicago, IL, USA

News - Nov. 12, 2018

AHA 2018 The TRED-HF evaluated well monitored withdrawal of pharmacological HF therapy and found that about 40% of patients deemed to have recovered DCM showed relapse.

ARNI lowers NT-proBNP and rehospitalization for HF in stabilized acute decompensated HF

AHA 2018 – Chicago, IL, USA

News - Nov. 12, 2018

AHA 2018 The results of the PIONEER-HF trial support the in-hospital initiation of sacubitril/valsartan in stabilized patients with acute decompensated heart failure and reduced EF.

SGLT2 inhibitor lowers HF hospitalization in both primary and secondary prevention T2DM patients

AHA 2018 – Chicago, IL, USA

News - Nov. 11, 2018
Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors in DECLARE TIMI-58, and with a modest decrease in MACE in those with existing ASCVD.

AHA 2018 Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors, and with a modest decrease in MACE in those with existing ASCVD.

Less HHF with SGLT2 inhibitor compared with DPP-4 inhibitors in T2DM with CVD in routine practice

News - Nov. 7, 2018

The real-world EMPRISE trial showed reduced risk for HF hospitalization with the SGLT2 inhibitor empagliflozin, compared with DPP-4 inhibitors in subjects with T2DM and CVD.

HFpEF: How to diagnose

HFpEF: The essentials to know

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA
There are several diagnostic approaches for HFpEF. Dr. Borlaug discusses their usefulness and limitations.

HFpEF: The essentials to know There are several diagnostic approaches for HFpEF. Dr. Borlaug discusses their usefulness and limitations.

Atrial fibrillation associated with worse long-term CV outcomes in HFmRF and HFpEF

Literature - Oct. 30, 2018 - Zafrir B et al. - Eur Heart J 2018

In patients with heart failure, compared with sinus rhythm, atrial fibrillation was associated with worse long-term cardiovascular outcomes in HFmrEF and HFpEF, but not in chronic or acute HFrEF.

HFpEF: What is it & size of the problem

HFpEF: The essentials to know

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands
Prof. Adriaan Voors gives a general overview on the history, epidemiology and prognosis of HFpEF

HFpEF: The essentials to know Prof. Adriaan Voors gives a general overview on the history, epidemiology and prognosis of HFpEF

Practical guidance on implementation of ESC recommendations on management of iron deficiency in chronic HF

News - Oct. 16, 2018

Despite specific recommendations on its management in the 2016 ESC Heart Failure Guidelines, iron deficiency is insufficiently diagnosed and treated in clinical practice. Practical guidance is now provided to complement the ESC Guidelines.

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Contemporary management of a patient with heart failure and diabetes: Implications from recent trials

CME accredited E-Learning

Online-CME - Online-CME - This course consists of 3 separate lectures
Online-CME - This course consists of 3 separate lectures

CME accredited course focussed on the management of patients with heart failure and diabetes. Member registration (free) is needed to enroll in this course